International Journal of Hematology

, Volume 108, Issue 2, pp 121–122 | Cite as

Activity of decitabine in pericardial myeloid sarcoma

  • Dorothea Evers
  • Brigitte M. A. M. Bär
  • Martin Gotthardt
  • Walter J. F. M. van der VeldenEmail author
Images in Hematology


Hypomethylating agent Decitabine Myeloid sarcoma Pericardium Acute myeloid leukemia 


Author contributions

DE and WJFMV wrote the manuscript. MG prepared the PET images. All authors were involved in the patient’s treatment. All authors revised and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

None of the authors has a conflict of interest to report in relation to this manuscript.


  1. 1.
    Gautam A, Jalali GK, Sahu KK, Deo P, Ailawadhi S. Cardiac myeloid sarcoma: review of literature. J Clin Diagn Res. 2017;11(3):XE01–04.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Gornicec M, Wolfler A, Stanzel S, Sill H, Zebisch A. Evidence for a role of decitabine in the treatment of myeloid sarcoma. Ann Hematol. 2017;96(3):505–6.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Dorothea Evers
    • 1
  • Brigitte M. A. M. Bär
    • 1
  • Martin Gotthardt
    • 2
  • Walter J. F. M. van der Velden
    • 1
    Email author
  1. 1.Department of HematologyRadboud University Medical CenterNijmegenThe Netherlands
  2. 2.Department of Radiology and Nuclear MedicineRadboud University Medical CenterNijmegenThe Netherlands

Personalised recommendations